Mural Health and Clinflash Announce Strategic Partnership
Mural Health has announced a strategic partnership with Clinflash. The partnership will expand the capacity and global market of patient payments for clinical trials. Having reached a global agreement, the partnership intends to enable sponsors to access patient payment solutions in the Chinese market and beyond.
Mural Health's participant management platform Mural Link™, has introduced a patient payments system and Clinflash ePAY (Clinical Trial Electronic Payment Solution) uses digital service technology to improve payment efficiency and security. The company has established close cooperation with key hospitals in China to provide third-party mobile payment solutions for Chinese trial participants.
Reference
Mural Health and China-based Clinflash Partner to Expand Global Patient Payment Solutions. (2023 May, 23). Cision PR Newswire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
